Magic Bullet Found for Dementia?!?

( – A new study found evidence that an inorganic chemical compound – sodium selenite – could be a “magic bullet” for stopping the cognitive decline of patients with dementia.

The peer-reviewed study discovered that using sodium selenite for treating patients with early stages of behavioral frontotemporal dementia could be vital for improving their condition.

Frontotemporal dementia is most common in patients over 65 and the second most common form of dementia in people younger than 65.

As a rapidly progressive disease, it usually attacks the elderly but can impact patients as young as 35.

Its symptoms include “disruptive behavior and unexpected personality changes.” Patients with the disease usually survive for 5-7 from the original diagnosis.

Scientists at Australia’s Monash University conducted the new research, informs The Jerusalem Post, as cited by Newsmax.

According to the researchers, the particular form of dementia could be treated with sodium selenite, which could stabilize the worsening behavioral issues it causes.

Their conclusions show sodium selenate was safe and well tolerated by the participants with behavioral variant frontotemporal dementia or bvFTD.

The yearlong study established that dementia patients on the medication experienced no behavioral problems or changes in cognition.

The researchers from Monash University point out that almost half of all recorded cases of bvFTD cause brain damage because of the buildup of a protein called tau.

Scientists have thus been seeking to figure out how to tackle the protein buildup.

The Australian scholars involved in the newly-released study found sodium selenite “instrumental in breaking down the tau protein.”

The medication could also decelerate substantially brain shrinkage caused by the disease.

“Sodium selenate’s second clinical trial showed the drug could have an impact on slowing cognitive decline and the brain damage that comes with many forms of dementia, such as Alzheimer’s Disease,” The Jerusalem Post informs.

“We have previously shown, in a Phase 2 trial, that sodium selenate given to patients with mild to moderate Alzheimer’s disease resulted in less neurodegeneration than in those who did not (receive it),” explained Dr. Lucy Vivash from Monash University’s Department of Neuroscience, the lead scientist in the study.

Monash University conducted the dementia study in cooperation with the Royal Melbourne Hospital, Australia’s only hospital and one of few in the world to work “on eradicating non-genetic bvFTD.”